Company Performance Metrics
- Halden Conner: CEO & President
Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications.
Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive
research providing prevention, treatments and cures for people affected by blinding retinal diseases.
FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.
